Promising Results from PEGASUS Trial Reported at ACC 2015

Video

Paul Spittle, vice president, Cardiovascular and Respiratory, AstraZeneca US, discusses results from the PEGASUS trial and explains what they may mean for heart attack and stroke risk in patients who have suffered a myocardial infarction.

In one of the most anticipated announcements at the 2015 American College of Cardiology annual meeting in San Diego, researchers presented early promising results from the PEGASUS trial, which compared treatment with ticagrelor and aspirin with aspirin alone.

Paul Spittle, vice president, Cardiovascular and Respiratory, AstraZeneca US, discusses results from the PEGASUS trial and explains what they may mean for heart attack and stroke risk in patients who have suffered a myocardial infarction.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.